Danantara Investment Management plans to invest US$2.5 billion for a 25% stake in a new protein-production joint venture with JBS, according to a 7 August filing by JBS with the US Securities and Exchange Commission. The proposed venture would cover Indonesia, other Southeast Asian markets, Australia and New Zealand.
How the proposed structure would work
Under the disclosed terms, JBS would place its Australia and New Zealand businesses into a new Dutch holding company before completion. Danantara’s investment arm would then subscribe for 25% of that company, while JBS would retain the remaining interest. U.S. Securities and Exchange Commission U.S. Securities and Exchange Commission
The filing also says the venture is expected to raise up to US$2.5 billion of external debt. That financing is a plan, not completed funding, and the filing does not establish that the full debt amount will be raised or deployed.
Why the transaction matters in Southeast Asia
JBS says the venture expects to consider greenfield projects, brownfield expansion and acquisitions across protein production in the covered markets. The stated geographic scope gives the transaction direct Southeast Asian relevance, but it does not identify a completed project pipeline or guarantee investment in any specific country.
What still has to happen
For the regional food economy, the proposed structure could connect large Australian and New Zealand production assets with investment and expansion opportunities in Indonesia and neighbouring markets. The practical questions are where new capacity would be built, how supply chains would be organised and which regulatory regimes would govern future projects.
Completion remains subject to required regulatory approvals, JBS transferring the Australia and New Zealand businesses to the venture, and other customary closing conditions. Until those conditions are met, the filing describes an agreed transaction structure rather than a completed investment.
Source note
SEA Connect based this brief on JBS’s 7 August Form 6-K and its filed material-fact exhibit. All investment, ownership, financing and expansion statements are attributed to that primary regulatory disclosure and remain subject to the conditions stated there.